We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current MYGN market cap is 1.75B. The company's latest EPS is USD -2.9296 and P/E is -6.64.
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 156.4M | 177.8M | 181.2M | 183.5M | 191.9M |
Operating Income | -34.3M | -62.9M | -52.2M | -113.7M | -60.1M |
Net Income | -35.1M | -42.3M | -54.7M | -116.1M | -61.3M |
Year End 31 December 2023 | 2020 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 641.4M | 299.8M | 690.6M | 678.4M | 753.2M |
Operating Income | -231.7M | -87.8M | -190.5M | -140.6M | -257.4M |
Net Income | -199.5M | -53.1M | -27.2M | -112M | -263.3M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 1.21B | 1.2B | 1.17B | 1.19B | 1.15B |
Total Liabilities | 295.4M | 312.9M | 334.1M | 452M | 465.7M |
Total Equity | 916.6M | 885.8M | 835.2M | 735.2M | 683.4M |
Year End 31 December 2023 | 2020 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 1.4B | 1.42B | 1.32B | 1.2B | 1.15B |
Total Liabilities | 486.4M | 537.8M | 352.9M | 312.9M | 363.3M |
Total Equity | 918.2M | 881M | 967.8M | 885.8M | 783.2M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -98.6M | -106.3M | -33.2M | -34.1M | -56.2M |
Investing | -41.9M | -77.5M | 34.6M | 46.4M | 43.9M |
Financing | -5.9M | -8M | -4.9M | 33.5M | 31M |
Year End 31 December 2023 | 2020 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 60.7M | -73.7M | 18.2M | -106.3M | -110.9M |
Investing | 19.3M | 28M | 274.4M | -77.5M | 31.9M |
Financing | -10M | -2.1M | -150.6M | -8M | 152.9M |
Market Cap | 1.75B |
Price to Earnings Ratio | -6.64 |
Price to Sales Ratio | 2.32 |
Price to Cash Ratio | 13.23 |
Price to Book Ratio | 2.23 |
Dividend Yield | - |
Shares Outstanding | 89.87M |
Average Volume (1 week) | 900.89k |
Average Volume (1 Month) | 623.25k |
52 Week Change | -9.25% |
52 Week High | 24.21 |
52 Week Low | 13.82 |
Spread (Intraday) | 3.47 (15.72%) |
Company Name | Myriad Genetics Inc |
Address |
corporation trust center wilmington, delaware 19801 |
Website | https://www.myriad.com |
Industry | in vitro,in vivo diagnostics (2835) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions